Liquidia Corporation develops and commercializes human therapeutics for the treatment of pulmonary arterial hypertension (PAH) and other applications using its proprietary particle engineering technology.
Employment range in NC
Primary site activity
Potential end market(s)
Products on market
Treprostinil Injection, the first-to-file, fully substitutable generic treprostinil for parenteral administration
Products under development
YUTREPIA, an investigational, inhaled dry powder formulation of treprostinil